Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
American Journal of Hematology (2018)
  • Anthony R. Mato, Memorial Sloan Kettering Cancer Center
  • Lindsey E. Roeker, Memorial Sloan Kettering Cancer Center
  • John N. Allan, Cornell University
  • John M. Pagel, Cancer Institute
  • Danielle M. Brander, Duke University
  • Brian T. Hill, Cancer Institute
  • Bruce D. Cheson, Georgetown University
  • Richard R. Furman, Cornell University
  • Nicole Lamanna, Columbia University Medical Center
  • Constantine S. Tam, University of Melbourne
  • Sasanka Handunnetti, University of Melbourne
  • Ryan Jacobs, Carolinas Healthcare System
  • Frederick Lansigan, Dartmouth–Hitchcock Medical Center
  • Erica Bhavsar, Cornell University
  • Paul M. Barr, University of Rochester Medical Center
  • Mazyar Shadman, Fred Hutchinson Cancer Research Center
  • Alan P. Skarbnik, Hackensack University Medical Center
  • Andre Goy, Hackensack University Medical Center
  • Douglas F. Beach, University of Pennsylvania
  • Jakub Svoboda, University of Pennsylvania
  • Jeffrey J. Pu, Pennsylvania State University
  • Alison R. Sehgal, University of Pittsburgh
  • Clive S. Zent, University of Rochester Medical Center
  • Hande H. Tuncer, Tufts Medical Center
  • Stephen J. Schuster, University of Pennsylvania
  • Peter V. Pickens, Abington Memorial Hospital
  • Nirav N. Shah, Medical College of Wisconsin
  • Joanna Rhodes, University of Pennsylvania
  • Chaitra S. Ujjani, Georgetown University
  • Chadi Nabhan, University of Chicago
Link
Disciplines
Publication Date
August 21, 2018
DOI
10.1002/ajh.25261
Citation Information
Anthony R. Mato, Lindsey E. Roeker, John N. Allan, John M. Pagel, et al.. "Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial" American Journal of Hematology (2018)
Available at: http://works.bepress.com/john-pagel/289/